Business
Vertex Pharmaceuticals Announces Webcast of its Presentation at the 26th Annual Canaccord Adams Summer Seminar
Vertex Pharmaceuticals Announces Webcast of its Presentation at the 26th Annual Canaccord Adams Summer Seminar.
About this update from Vortex Energy Corp.
[{"type":"text","content":"\n\n\n\n\nCAMBRIDGE, Mass., Aug. 2 /CNW/ -- Vertex Pharmaceuticals\nIncorporated (Nasdaq: VRTX) will webcast its corporate presentation at the\n26th Annual Canaccord Adams Summer Seminar. John Alam, M.D., Executive Vice\nPresident, Medicines Development and Chief Medical Officer of Vertex, will\ndeliver the presentation on Tuesday, August 8, 2006 at 8:30 a.m. EDT.\nThe presentation will be webcast live and may be accessed by visiting the\nVertex website at http://www.vrtx.com. A replay of the webcast will also be\navailable on the Company's website until August 22, 2006. To access the\nwebcast, go to Vertex's website and select the 'Canaccord Adams 2006 Summer\nSeminar.' To ensure a timely connection, it is recommended that users\nregister at least 15 minutes prior to the scheduled webcast.\n\nAbout Vertex\nVertex Pharmaceuticals Incorporated is a global biotechnology company\ncommitted to the discovery and development of breakthrough small molecule\ndrugs for serious diseases. The Company's strategy is to commercialize its\nproducts both independently and in collaboration with major pharmaceutical\ncompanies. Vertex's product pipeline is principally focused on viral\ndiseases, inflammation, autoimmune diseases and cancer. In collaboration with\nGlaxoSmithKline, Vertex co-discovered the HIV protease inhibitor, Lexiva.\n\nLexiva is a registered trademark of the GlaxoSmithKline group of\ncompanies.\n\nVertex's press releases are available at http://www.vrtx.com.\n\nVertex Contact:\nLora Pike, Manager, Investor Relations, (617) 444-6755\n\n\n\n","length":1624,"tagName":"div"}]